Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer

BACKGROUND: In the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Cascinu, Stefano, Bodoky, György, Muro, Kei, Van Cutsem, Eric, Oh, Sang Cheul, Folprecht, Gunnar, Ananda, Sumitra, Girotto, Gustavo, Wainberg, Zev A., Miron, Maria Luisa Limon, Ajani, Jaffer, Wei, Ran, Liepa, Astra M., Carlesi, Roberto, Emig, Michael, Ohtsu, Atsushi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2020
Aiheet:
Gastrointestinal Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930430/
https://ncbi.nlm.nih.gov/pubmed/33274542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13623
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia